Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Sonelokimab in Psoriatic arthritis. The expected timing is based on the latest available company guidance and may change.
ARGO, IZAR-1, IZAR-2 trials. 3/10/24- Reported positive 24-wk data. 8/7/24- Enroll subjects in Q4 2024. 11/13/24- starts Ph3 IZAR program. 5/12/25- Trial ongoing. 8/5/25- Topline week-16 data in H1 2026 11/05/25:- IZAR-1 primary endpoint readout expected Q2 2026; IZAR-2 primary endpoint readout anticipated in H2 2026. 02/02/26:- IZAR-1 primary endpoint readout now guided for Mid-2026; IZAR-2 readout reiterated for H2 2026. 02/22/26:- IZAR-1 Phase 3 PsA primary endpoint readout reiterated for Mid-2026; IZAR-2 readout reiterated for H2 2026. 05/10/26:- Mid-2026 IZAR-1 and Q4 2026 IZAR-2 primary endpoint readouts confirmed as key PsA catalysts. 06/21/26:- IZAR-1 readout reiterated for Mid-2026; IZAR-2 readout guided for H2 2026. 08/10/26:- IZAR-1 Week 16 data positive. Full readout H1 2027. IZAR-2 enrollment completes Q3 2026.
Verification
Confirm timing and program details against the company announcement or filing.